US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
AR030379A1
(es)
*
|
2000-08-22 |
2003-08-20 |
Novartis Ag |
Combinaciones
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
DE50111751D1
(de)
*
|
2000-12-21 |
2007-02-08 |
Sanofi Aventis Deutschland |
Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
|
KR100838422B1
(ko)
*
|
2001-05-28 |
2008-06-16 |
가오가부시끼가이샤 |
지방분해 촉진제 및 이를 함유하는 체중감량용 피부화장료, 음식품 조성물 및 그 작용에 기초하는 체중 감량 방법
|
US7025985B2
(en)
*
|
2001-05-28 |
2006-04-11 |
Kanebo, Ltd. |
Dihydroxyphenyl compounds and glucoside compounds thereof
|
US6987123B2
(en)
*
|
2001-07-26 |
2006-01-17 |
Cadila Healthcare Limited |
Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
|
AU2002336532C1
(en)
|
2001-09-14 |
2008-10-16 |
Amgen, Inc |
Linked biaryl compounds
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
AR039090A1
(es)
*
|
2002-03-22 |
2005-02-09 |
Novartis Ag |
Combinacion de compuestos organicos
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
AU2003225027A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Merck And Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|
ITMI20021012A1
(it)
*
|
2002-05-13 |
2003-11-13 |
Giovanni Scaramuzzino |
Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato
|
EP1388352A1
(en)
*
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
|
NZ538031A
(en)
*
|
2002-08-29 |
2007-10-26 |
Merck & Co Inc |
Indoles having anti-diabetic activity
|
EP1546142A4
(en)
*
|
2002-08-29 |
2007-10-17 |
Merck & Co Inc |
INDOLES HAVING ANTIDIABETIC EFFECT
|
JP4286782B2
(ja)
|
2002-09-12 |
2009-07-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
糖尿病の治療に有用な、pparアゴニストとしてのn−置換−1h−インドール−5−プロピオン酸化合物
|
DE10300099A1
(de)
*
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Indol-Phenylsulfonamid-Derivate
|
KR20110010824A
(ko)
|
2003-01-14 |
2011-02-07 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
|
ATE490244T1
(de)
|
2003-01-27 |
2010-12-15 |
Merck Sharp & Dohme |
Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
|
AU2004231106A1
(en)
*
|
2003-04-14 |
2004-10-28 |
The Institutes For Pharmaceutical Discovery, Llc |
N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
|
CA2523714A1
(en)
|
2003-04-30 |
2004-11-18 |
The Institutes For Pharmaceutical Discovery, Llc |
Substituted carboxylic acids
|
WO2004098510A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Beth Israel Deaconess Medical Center |
Cystic fibrosis therapy
|
US7981915B2
(en)
*
|
2003-04-30 |
2011-07-19 |
Beth Israel Deaconess Medical Center |
Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
US20060160834A1
(en)
*
|
2003-06-06 |
2006-07-20 |
Fong Tung M |
Combination therapy for the treatment of hypertension
|
WO2004108126A1
(en)
*
|
2003-06-06 |
2004-12-16 |
Snowden Pharmaceuticals, Llc |
Fibric acid derivatives for the treatment of irritable bowel syndrome
|
JP4920410B2
(ja)
|
2003-07-14 |
2012-04-18 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
|
DE10335449A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Healthcare Ag |
Bicyclische Indolinsulfonamid-Derivate
|
DE10337839A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Bayer Healthcare Ag |
Indolin-Derivate
|
US20050074443A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Treadwell Benjamin V. |
Methods of attenuating autoimmune disease and compositions useful therefor
|
BRPI0416238A
(pt)
*
|
2003-11-05 |
2007-01-02 |
Hoffmann La Roche |
compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa)
|
MXPA06004641A
(es)
*
|
2003-11-05 |
2006-06-27 |
Hoffmann La Roche |
Derivados de fenilo como agonistas para.
|
KR100849352B1
(ko)
|
2003-11-05 |
2008-07-29 |
에프. 호프만-라 로슈 아게 |
Ppar 활성화제로서 벤조-융합된 화합물
|
EP1689389A4
(en)
|
2003-12-04 |
2009-06-17 |
Nat Health Research Institutes |
Indole compounds
|
JP2005200419A
(ja)
*
|
2004-01-16 |
2005-07-28 |
National Health Research Inst |
癌治療法
|
JP2007534702A
(ja)
*
|
2004-04-26 |
2007-11-29 |
バンダービルト・ユニバーシティ |
胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
|
US20080076810A1
(en)
*
|
2004-05-28 |
2008-03-27 |
Weiguo Lui |
Benzoureas Having Anti-Diabetic Activity
|
AU2005247110B2
(en)
*
|
2004-05-29 |
2010-08-26 |
7Tm Pharma A/S |
CRTH2 receptor ligands for medicinal uses
|
DE602005006806D1
(de)
*
|
2004-06-04 |
2008-06-26 |
Merck & Co Inc |
Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
|
WO2006014262A2
(en)
|
2004-07-02 |
2006-02-09 |
Merck & Co., Inc. |
Indoles having anti-diabetic activity
|
EP1773330B1
(en)
|
2004-07-22 |
2010-05-26 |
Merck Sharp & Dohme Corp. |
Substituted pyrazoles, compositions containing such compounds and methods of use
|
ES2313401T3
(es)
|
2004-07-30 |
2009-03-01 |
Laboratorios Salvat, S.A. |
Derivados de tirosina como moduladores de ppar-gamma.
|
US20060205669A1
(en)
*
|
2004-09-16 |
2006-09-14 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
JP2008019169A
(ja)
*
|
2004-10-25 |
2008-01-31 |
Osaka Univ |
新規ppar調節剤およびそのスクリーニング方法
|
AU2005307718A1
(en)
*
|
2004-11-18 |
2006-05-26 |
The Institutes For Pharmaceutical Discovery, Llc |
Heterocycle substituted carboxylic acids for the treatment of diabetes
|
CN101115496B
(zh)
|
2004-12-06 |
2012-03-07 |
加州大学评议会 |
改善微动脉的结构和功能的方法
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
FR2880887B1
(fr)
*
|
2005-01-14 |
2009-01-30 |
Merck Sante Soc Par Actions Si |
Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
|
MX2007010745A
(es)
|
2005-03-04 |
2007-09-12 |
Merck & Co Inc |
Compuestos aromaticos fusionados con actividad anti-diabetica.
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
MX2007013430A
(es)
*
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
CN101184484B
(zh)
*
|
2005-05-24 |
2011-10-05 |
帝斯曼知识产权资产管理有限公司 |
用于治疗炎性失调的藁本内酯衍生物
|
CA2612765A1
(en)
|
2005-07-06 |
2007-01-18 |
Merck And Co., Inc. |
Antidiabetic oxazolidinediones and thiazolidinediones
|
US7709658B2
(en)
|
2005-07-26 |
2010-05-04 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a substituted pyrazole
|
US20070161006A1
(en)
*
|
2006-01-10 |
2007-07-12 |
Vita Genomics, Inc. |
Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
|
DK1971862T3
(da)
*
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
CN101528222A
(zh)
|
2006-06-19 |
2009-09-09 |
范德比尔特大学 |
用于诊断性和治疗性靶向cox-2的方法和组合物
|
KR20090066289A
(ko)
|
2006-09-08 |
2009-06-23 |
로드아일랜드하스피틀 |
알코올 유발성 뇌 질환의 치료, 예방 및 역행
|
ES2547386T3
(es)
|
2007-01-26 |
2015-10-05 |
Kaneq Pharma Inc. |
Inhibidores de la PTP-1B aromáticos condensados
|
CN101622230B
(zh)
|
2007-02-26 |
2012-08-22 |
默克弗罗斯特加拿大有限公司 |
作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物
|
US8338458B2
(en)
|
2007-05-07 |
2012-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
FR2921366B1
(fr)
*
|
2007-09-26 |
2009-12-04 |
Servier Lab |
Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
DE102007054497B3
(de)
*
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
EP2108960A1
(en)
*
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
CA2749891A1
(en)
|
2009-01-23 |
2010-07-29 |
Hubert B. Josien |
Bridged and fused antidiabetic compounds
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
WO2010091176A1
(en)
|
2009-02-05 |
2010-08-12 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011019538A1
(en)
|
2009-08-13 |
2011-02-17 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
KR20120092096A
(ko)
|
2009-09-02 |
2012-08-20 |
머크 샤프 앤드 돔 코포레이션 |
당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-iv 억제제로서의 아미노테트라히드로피란
|
US8754099B2
(en)
|
2010-01-15 |
2014-06-17 |
Merck Sharp & Dohme Corp |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
WO2011103256A1
(en)
|
2010-02-22 |
2011-08-25 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
EP2563764B1
(en)
|
2010-04-26 |
2015-02-25 |
Merck Sharp & Dohme Corp. |
Novel spiropiperidine prolylcarboxypeptidase inhibitors
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
EP2571876B1
(en)
|
2010-05-21 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
CN103347385A
(zh)
|
2010-10-29 |
2013-10-09 |
默沙东公司 |
二醇二氮烯鎓类杂环衍生物
|
US8933113B2
(en)
|
2011-01-20 |
2015-01-13 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
CA2831334A1
(en)
|
2011-04-08 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2697203B1
(en)
|
2011-04-13 |
2017-05-24 |
Merck Sharp & Dohme Corporation |
Mineralocorticoid receptor antagonists
|
WO2012151114A1
(en)
|
2011-05-02 |
2012-11-08 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
BR112013030883A2
(pt)
|
2011-06-02 |
2017-10-10 |
Intervet Int Bv |
composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma condição selecionada do grupo consistindo em obesidade e diabete
|
US9006228B2
(en)
|
2011-06-16 |
2015-04-14 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2012178142A1
(en)
*
|
2011-06-23 |
2012-12-27 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
|
EP2760855B1
(en)
|
2011-09-30 |
2017-03-15 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
|
WO2013055606A1
(en)
|
2011-10-13 |
2013-04-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
WO2013059245A1
(en)
|
2011-10-17 |
2013-04-25 |
Vanderbilt University |
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
|
WO2013062838A1
(en)
|
2011-10-24 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as gpr119 agonists
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
JP6101279B2
(ja)
|
2011-11-15 |
2017-03-22 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Gpr119アゴニストとして有用な置換シクロプロピル化合物
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US20150057220A1
(en)
|
2012-04-16 |
2015-02-26 |
Kaneq Pharma Inc. |
Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
US9453038B2
(en)
|
2012-12-17 |
2016-09-27 |
Merck Sharp & Dohme Corp. |
Glucokinase activator compounds, compositions containing such compounds, and methods of treatment
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
EP3097101B1
(en)
|
2014-01-24 |
2020-12-23 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as mgat2 inhibitors
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2016018729A1
(en)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
CN107074923B
(zh)
|
2014-07-31 |
2021-08-03 |
Uab研究基金会 |
Apoe模拟肽及对清除血浆胆固醇的较高效力
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10413593B2
(en)
|
2014-10-24 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and GLP-1 receptors
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
WO2016191334A1
(en)
|
2015-05-27 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
US10213429B2
(en)
|
2015-05-28 |
2019-02-26 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
KR102603199B1
(ko)
|
2015-06-22 |
2023-11-16 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
|
WO2017011279A1
(en)
|
2015-07-13 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
EP3359191A4
(en)
|
2015-10-05 |
2019-05-29 |
Merck Sharp & Dohme Corp. |
ANTIBODY-PEPTIDE CONJUGATES HAVING AGONIST ACTIVITY AT GLUCAGON AND PEPTIDE-1 RECEPTORS SIMILAR TO GLUCAGON
|
WO2017095725A1
(en)
|
2015-11-30 |
2017-06-08 |
Merck Sharp & Dohme Corp. |
Aryl sulfonamides as blt1 antagonists
|
EP3383868B1
(en)
|
2015-11-30 |
2022-10-05 |
Merck Sharp & Dohme LLC |
Aryl sulfonamides as blt1 antagonists
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
US10414774B2
(en)
|
2016-08-15 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
|
US10414775B2
(en)
|
2016-08-15 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
WO2018057409A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
|
MA46859A
(fr)
|
2016-11-18 |
2019-09-25 |
Merck Sharp & Dohme |
Dérivés d'indole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
WO2018151873A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
EP3946324A4
(en)
|
2019-04-04 |
2022-11-30 |
Merck Sharp & Dohme LLC |
HISTONE DEACETYLASE-3 INHIBITORS USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATIVE DISEASES AND DIABETES
|
WO2020236688A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
WO2020236690A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
WO2021041770A1
(en)
|
2019-08-30 |
2021-03-04 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
WO2021236401A1
(en)
|
2020-05-18 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Novel diacylglyceride o-acyltransferase 2 inhibitors
|
KR20240050369A
(ko)
|
2021-08-19 |
2024-04-18 |
머크 샤프 앤드 돔 엘엘씨 |
Pcsk9 활성과 관련된 상태를 치료하기 위한 화합물
|
US20230406885A1
(en)
|
2022-06-15 |
2023-12-21 |
Merck Sharp & Dohme Llc |
Cyclic peptides for trapping interleukin-1 beta
|